
    
      Participants in prophylaxis arm will receive a weekly prophylactic dose of BIVV001 for 52
      weeks. Participants in on-demand arm will receive BIVV001 on demand for 26 weeks followed by
      a switch to weekly prophylaxis for another 26 weeks.

      The Sponsor plans to perform a long-term safety trial. Enrollment in this open-label
      extension study will be offered to patients completing the treatment period based on
      eligibility criteria.
    
  